Pharmaceutical Industries Ltd.
Your browser does not support iframes.
See Teva's sites around the world
Japan & S. Korea
Bosnia & Herzegovina
Want to find out more about Teva's locations and phone numbers?
Visit Teva Worldwide
Board of Directors
2017 Annual Report – Form 10-K
Notice of Annual Meeting of Shareholders 2017 – Proxy Statement
Over the Counter (OTC)
Central Nervous System (CNS)
National Network of Excellence
Position on Antimicrobial Resistance (AMR)
2016 Social Impact Report
Previous CSR Reports
Supplier Code of Conduct & Information for Our Suppliers
Global Patient Organization and Advocacy Disclosure
Four New Independent Directors Join the Teva Board
Webcasts and Presentations
Dare to be different
Our Guiding Values
Working at Teva
Grow with the Best
Go to Parent
New Therapeutic Entities (NTEs)
Personalized Medicine is increasingly being used to tailor medical treatment to the individual characteristics of each patient: The right treatment, at the right dose, for the right person.
Share on Facebook
Share on LinkedIn
Share on Twitter
Right Treatment, Right Dose, Right Patient
Using pharmacogenomics, biomarkers and other targeted therapeutic methods, Personalized Medicine supports the development and use of therapies designed specifically for patients who will benefit from them and will tolerate them.
Matching Patients to Treatments
By matching patients to the best treatments based on their genetic profile and other predictive factors, Personalized Medicine is changing the way drugs are developed and prescribed. It offers significant potential for improving patient quality of life and quality of care across a broad range of diseases and conditions.
We are placing a growing focus on personalized medicine, integrating it across our R&D pipeline. Our Personalized Medicine and Pharmacogenomics (PMP) unit, within the R&D group, designs a "tailor-made" PMP approach (harnessing pharmacogenetics, expression profiling, biomarkers, combined modalities, and others) for each specific discovery and development program, and for each specific stage of that program.
In this way, Teva’s R&D group is able to address the increasing demands of regulators, healthcare providers and payers for greater precision in predicting the efficacy and safety of treatments. Moreover, the predictive power of Personalized Medicine is being harnessed to reduce attrition and increase success of proof-of-concept trials. Additionally, it supports regulatory filings, enhances market acceptance, improves pharmacovigilance and strengthens physician and patient confidence in our medicines.